Tom Foley Named VP, Growth at GenieMD

Tom Foley in the News

Tom Foley has been named Vice President of Growth at GenieMD. Foley brings more than 30 years of experience in information technology to this new role, having led numerous transformative initiatives both in and out of healthcare. Most recently, Foley held leadership positions at AMD and Cerner, where he was responsible for consumer strategy including telehealth, remote patient monitoring, portal, CRM and mobile apps across the federal market.

“We are extremely pleased to welcome Tom to our growing team at GenieMD,” said Soheil Saadat, PhD, CEO of GenieMD. “We’re confident that Tom’s years of health IT experience, wealth of healthcare knowledge and considerable business development proficiency will be an asset to our organization.”

“I’m looking forward to leading the strategic growth of GenieMD by further advocating the new norms and models necessary to embrace a virtual care delivery model,” Foley said.

In addition to his position with GenieMD, Foley currently hosts The Virtual Shift, a HealthcareNOWradio.com podcast focused on reimagining the delivery of care. He has also moderated the Health Innovation Think Tank (HITT), an executive collaborative  made up of 50 healthcare delivery system, payer organization and healthcare IT vendor thought leaders who offer their insights leading to establishment of best practices on a variety of issues associated with value based care, connected health and virtual care. He served for two years on the Board of the UPMC Center for Connected Medicine.

Previously, he held leadership roles at Lenovo, Allscripts, Thomson Healthcare and other national technology firms. Among his professional achievements, Foley was lead collaborator to transform UPS call centers from paper to electronic caapture, and contributed to the rollout of the first national wireless data networks. He is the former President of iPatientCare, a cloud-based EHR, and led the launch of patient ports to over 15 million subscribers and the largest initial release of direct messaging to 43,000 subscribers.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”